

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قال الله تعالى

**لِلَّهِ مُلْكُ السَّمَوَاتِ وَالْأَرْضِ يَخْلُقُ مَا يَشَاءُ يَهَبُ لِمَنْ يَشَاءُ
إِنَاثًا وَيَهَبُ لِمَنْ يَشَاءُ الذَّكَوَر (49) أَوْ يُرَوِّجُهُمْ ذُكْرَانًا
وَإِنَاثًا وَيَجْعَلُ مَنْ يَشَاءُ عَقِيمًا إِنَّهُ عَلِيمٌ قَدِيرٌ (50)**

صدق الله العظيم

سورة الشورى الآيات 49-50

Dedication

I dedicate this research to

The people whose prayers help me and encourage me to the way success..

My mother

To my father

My brothers and sisters

My friends and my colleagues

The people, whom I love, respect and appreciate and everyone from whom I learned.....

Acknowledgment

First of all I thank Allah for giving me the strength and patience to perform this work,.i would like to express the my deepest gratitude and respect to

Dr.Mohieldin Abass Abdulla Elsayid for his supervision, time, patience effort and invaluable advices, I would like to express my thank to the staff of dialysis center in Alribbat Hospital , my colleagues and friends for their support and help throughout study, to everybody who contributed to the success of this work.

Abstract

This is a descriptive analytical study carried out in Khartoum state during the period of March 2012 to July 2012, to evaluate some haemostatic parameters among liver diseases patient. Fifty samples with diagnosed liver disease, were selected, and twenty five healthy individual were selected as control group. The study population were liver disease patients that include two gall cholecystitis (4 %) , six obstructive jaundice (12%) , eleven liver cirrhosis (22.0%) , eighteen HBV (36%) , eleven HCV (22%) , and two liver metastasis (4%). The gender distribution were females 33 (44.7 %) , and males 42 (55.3%). The marital status among the study population was married 46 (60.5%) and single 29 (39.5%). , 2.5 ml of venous blood withdrawn from each patient and control, placed in trisodium citrate container, then centrifuged to obtain platelets poor plasma (PPP) for measuring Prothrombin time (PT), activated thromboplastin time (APTT), thrombin time (TT) and fibrinogen level. . The compare mean of liver diseases each alone include that PT of cirrhosis , jaundice , HBV , HCV, Gallcholecystitis, and liver metastasis are (20.0sec) . The results were analyzed by SPSS version 11.5 and express as means; the results obtained showed that the means of PT (17.0sec), APTT (40.0sec), TT (19.0sec) and fibrinogen level (262.0mg/dl) respectively. The mean of PT, PTT, TT, and fibrinogen level of control group were (13.0sec), (31.0sec), (13.0sec), and (222.0mg/dl) respectively. The results showed highly significant differences between the mean values of patients in compare to controls in Prothrombin time PT (P.value <0.05), activated partial thromboplastin time APTT (P.value <0.05), thrombin time TT (P.value <0.05) and fibrinogen level (P.value <0.05). The result show

insignificant differences between age groups, sex ,marital status ,and disease types .

ملخص البحث

هذه دراسة وصفية تحليلية أجريت في ولاية الخرطوم في الفترة من مارس 2012 الي يوليو 2012 لقياس بعض معاملات التجلط لدي مرضي الكبد السودانيين, تم اختيار خمسون من مرضي الكبد مشخصين مسبقا كما تم أخذ خمسة وعشرون عينة من اصحاء كمجموعة ضابطة. تم أخذ 2.5 مليلتر من الدم الوريدي من كل مريض وتم وضعه في حاوية تحتوي علي مانع التجلط ثلاثي سترات الصوديوم واستخلص سائل البلازما فقير الصفائح الدموية لقياس, زمن البروثرومبين , زمن الثرومبوبلاستين الجزئ المنشط , زمن الثرومبين, ومستوي الفبرينوجين وتم تحليل النتائج بواسطة برنامج الحزم الاحصائية للعلوم الاجتماعية المحوسب اصدارة 11.5 , شملت الدراسة من امراض الكبد تليف الكبد(11) اليرقان الانسدادي(6) التهاب المراره(2) التهاب الكبد الوبائي النوع ب(18) التهاب الكبد النوع س(11) واورام الكبد(2) من المرضي اظهرت الدراسة نسب امراض الكبد كالاتي تليف الكبد (22%) اليرقان الانسدادي (12%) التهاب المراره(4%) التهاب الكبد الوبائي النوع ب(36%) التهاب الكبد النوع س(22%) واورام الكبد (45%) شملت الدراسة من الذكور 30(55.3%) ومن الاناث 20 (44.7%) المتزوجين 31(60.5%) وغير المتزوجين 29 (39.5%). تم حساب المتوسط وكانت النتائج كالاتي: زمن البروثرومبين (17ثانيه) زمن الثرومبوبلاستين الجزئ المنشط (40ثانيه) الثرومبين(19ثانيه) ومستوي الفبرينوجين(262ملجرام\مللداستر) للمرضي بينما كان المتوسط للبروثرومبين (13ثانيه) الثرومبوبلاستين الجزئ المنشط (31ثانيه) الثرومبين (13ثانيه) ومستوي الفبرينوجين(222ملجرام للداستر) في مجموعة الضبط. اظهرت النتائج وجود فروقات ذات دلالة احصائية معنويه بين المصابين بامراض الكبد في متوسطات البروثرومبين زمن الثرومبوبلاستين المنشط الجزئ زمن الثرومبين ومستوي الفبرينوجين (القيمه المعنويه اقل من 0.05). مقارنة بعيينات المعادليين الطبيعيين ايضا لم تظهر الدراسة فروق ذات دلالة احصائية بين الاجناس وايضا بين المتزوجين وغير المتزوجين

لكن اظهرت فروق ذات دلالة احصائية بين الاعمار (القيمة المعنوية اقل من 05.)

Contents

No.	Contents	Page
1.	الآية	I
2.	Dedication	II
3.	Acknowledgement	III
4.	Abstract (English)	IV
5.	Abstract (Arabic)	V
6.	List of contents	VI
7.	List of Tables	XII
8.	List of abbreviations	XIII
	Chapter One	
	Introduction and Literature review	
1.1	General introduction	1
1.2	Literature Review	2
1.2.1	Hemostasis	2
1.2.1.1	Definition of haemostasis	2
1.2.1.2	Overview of haemostasis	3
1.2.1.3	Component of the heamostatic system	3

1.2.1.3.1	Blood vessel	5
1.2.3.2	Platelets	5
1.2.1.3.3	Coagulation system	7
1.2.1.3.3.1	Coagulation factors	10
1.2.1.3.3.2	Coagulation inhibitors	11
1.2.1.2.2.2	Haemostatic mechanism	12
1.2.1.4.1	Primary haemostasis	12
1.2.1.4.2	haemostasis	14
1.2.1.4.3	Fibrinolysis	16
1.2.1.5	Laboratory test of haemostasis:	17
1.2.1.5.1	Samples for coagulation testing	17
1.2.1.5.5	First line investigations:	18
1.2.1.5.3	Second line investigations:	20
1.2.1.6	Disorder of haemostasis:	21
1.2.1.6.1	Platelets disorders:	20
1.2.1.6.1.1. 1	Thrombocytopenia	20
1.2.1.6.1.1. 2	thrombocytosis	22
1.2.1.6.1.2	Qualitative platelets disorders	22

1.2.1.6.1.2.1	Hereditary qualitative platelets disorders:	22
1.2.1.6.1.2.2	Acquired qualitative platelets disorders	23
1.2.1.6.2.1	Inherited vascular disorders:	24
1.2.1.6.2.3	Lab diagnosis of vascular and platelets disorders	25
1.2.1.6.3	Coagulation disorders	26
1.2.1.6.3.2	Acquired coagulation disorders	32
1.3	The liver	34
1.3.1	Liver Diseases	35
1.3.2	Type of liver disease	36
1.3.2.1	Alcoholic Liver Disease:	37
1.3.2.2	Fatty Liver Diseases	37
1.3.3.3	Biliary Diseases:	37
1.3.3.4	Chronic Hepatitis	37
1.3.3.5	Liver Cirrhosis	37
1.4.0	Previous studies	41
1.5	Rationale:	42
1.5.1	General Objective	43

1.5.2	Specific Objective:	43
	Chapter Two Materials and Methods	
2.1	Study design	44
2.2	Study areas	44
2.3	Study population	44
2.4	Criteria	44
2.5	Exclusion Criteria	44
2.6	Sample size	44
2.7	Ethical consideration	45
2.8	Tool of data collection	45
2.9	Data analysis	46
2.10	Preparation of platelet poor plasma.	46
2.11	Methods	46
2.11.1	Thrombin time(TT)	47
2.11.2	Prothrombin time(PT)	48
2.11.3	Activated partial Thromboplastin.(APTT)	49
2.11.4	Fibrinogen level	49
3	Chapter Three Results	51
4	Chapter Four	61

	Discussion, conclusion and recommendations	
4	References and appendices	65
4.1	References	65
4.2	appendixes	68

Tables

NO	Name of the Table	Page
1.1	<i>coagulation factor and relative substance</i>	10
1.2	<i>coagulation factor and relative substance</i>	11
1.2	Fibrinogen Levels of Controls and Patients of Cirrhosis	38
1.3	Fibrinogen Levels in Uncomplicated and Complicated Liver Cirrhosis	39
1.4	coagulation marker in each group of patient	40
1.5	statistical tests of mean against reference constants, correlation for study group	41
3.1	Demographic characteristic of study participants	50
3.2	Demographic of diseases types	51
3.3	Compare mean of parameters of case and control	52
3.4	Mean, SD, minimum, and maximum, of coagulation parameters in test group.	53
3.5	Mean, SD, minimum, and maximum, of control group	54

3.6	Effect of age group on the study of coagulations parameters	55
3.7	Mean of PT, PTT, TT, and fibrinogen among sex group of liver	56
3.8	mean of study group according to marital status	57
3.9	Mean of coagulation parameters PT, PTT, with liver disease types	58
3.10	Mean of coagulation parameters TT, fibrinogen, with liver disease	59

Abbreviations

ADP	Adenosine diphosphate.
AT	Anti thrombin.
BSS	Bernard Soulier Syndrome.
CT	Clotting time.
DIC coagulation.	Disseminated intravascular
DVT	Deep venous thrombosis.
EDTA	Ethylene diamine tetra acetic acid.
FDPs	Fibrin degradation product.
GP	Glycoprotein.
HMWK	High molecular weight kininogen.
PAI-1	Plasminogen activator inhibitor.
PPP	platelet poor plasma.
PDGF	Platelet derived growth factor.
TPA	Tissue plasminogen activator.
vWF	von will brand factor.